Filing Details

Accession Number:
0001225208-18-001321
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2018-01-19 17:30:06
Reporting Period:
2018-01-12
Accepted Time:
2018-01-19 17:30:06
Original Submission Date:
2018-01-16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
310158 Merck & Co. Inc. MRK Pharmaceutical Preparations (2834) 221918501
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1168014 M Mirian Weir Graddick Merck & Co., Inc.
2000 Galloping Hill Road
Kenilworth NJ 07033
Exe V-P, Hr No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-01-12 8,000 $58.00 98,484 No 4 S Direct
Common Stock Acquisiton 2018-01-16 52,000 $44.30 150,484 No 4 M Direct
Common Stock Disposition 2018-01-16 8,000 $61.63 142,484 No 4 S Direct
Common Stock Disposition 2018-01-16 52,000 $61.63 90,484 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The sale reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan.
  2. The original Form 4, filed on January 16, 2018, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported a sale that occurred on January 12, 2018 as a total of 5,000 shares sold when in fact 8,000 shares of the Issuer's common stock were sold. As a result of this administrative error, the number of shares beneficially owned by the reporting person following the corrected transaction reflects a reduction in the number of shares reported as beneficially owned by the reporting person by 3,000 shares, and includes shares acquired in dividend reinvestment transactions.
  3. The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.